REG-Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update
Globe Newswire•10/08/2026•16:01 ET
0
Whiz Insights
Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager
Forecast at least €1.6B of cash remaining after funding portfolio to first gamgertamig approval
Get started
Create a free account to read the full story.